The Medicines Company (NASDAQ:MDCO) last issued its quarterly earnings data on Wednesday, April 23rd. The company reported ($0.08) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.07) by $0.01. The company had revenue of $177.20 million for the quarter, compared to the consensus estimate of $175.60 million. During the same quarter last year, the company posted ($0.21) earnings per share. The Medicines Company’s revenue was up 13.7% compared to the same quarter last year. The Medicines Company (NASDAQ:MDCO) stock performance was 5.30% in last session and finished the day at $27.24. Traded volume was 739,551 shares in the last session and the average volume of the stock remained 1.01 million shares. The beta of the stock remained 0.79. The Medicines Company (NASDAQ:MDCO) insider ownership is 1.00%.

Omeros Corporation (NASDAQ:OMER) and Ventiv Commercial Services, LLC, an inVentiv Health company (“Ventiv”), On May 22, 2014 entered into a Project Agreement pursuant to which Ventiv will provide to Omeros a field force of 20 Ventiv sales representatives, a part time national business director and a part time operations manager, to provide detailing services and sales operation services related to Omidria, if approved. The Project Agreement has a two-year term from the date of deployment of the Ventiv sales representatives (the “Effective Date”).Omeros Corporation (NASDAQ:OMER) rose 12.00% to $11.67  on Friday on volume of 518,448 shares. The intra-day range of the stock was $10.17 – 11.76. Omeros Corporation (NASDAQ:OMER) has a market capitalization of $395.76 million.

Northwest Biotherapeutics, Inc (NASDAQ:NWBO) posted its quarterly earnings results on Wednesday. The company reported ($0.46) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.33) by $0.13, Analyst Ratings Network.com reports. Northwest Biotherapeutics, Inc (NASDAQ:NWBO)’s stock on May 23, 2014 reported a increase 5.42% to the closing price of $5.83. Its fifty two weeks range is $3.10 – 10.64. The total market capitalization recorded $ 333.45 Million. The overall volume in the last trading session was 353,029 shares. In its share capital, Northwest Biotherapeutics, Inc (NASDAQ:NWBO) has 57.20 million outstanding shares.

Dehaier Medical Systems Ltd (NASDAQ:DHRM), an emerging leader in the development, assembly, marketing and sale of medical devices and sleep respiratory products in China, on April 30, 2014 announced it has become the authorized agent of Olympus (Beijing) Sales & Service Co., Ltd. to supply its electronic gastroscope and electronic bronchoscope products to participate in several medical device procurement projects funded by the Chinese government. Pursuant to the authorization letter with Olympus, Dehaier will be responsible for bidding, agreement negotiation and execution of the projects. On Friday, shares of Dehaier Medical Systems Ltd (NASDAQ:DHRM) advanced 15.00% to close the day at $6.67. Company return on investment (ROI) is 7.80% and its monthly performance is recorded as 7 8.99%. Dehaier Medical Systems Ltd (NASDAQ:DHRM) quarterly revenue growth is -37.49%.

Durata Therapeutics Inc (NASDAQ:DRTX) last announced its earnings results on Thursday, May 8th. The company reported ($0.62) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.64) by $0.02. On average, analysts predict that Durata Therapeutics will post $-2.42 earnings per share for the current fiscal year. On Friday, shares of Durata Therapeutics Inc (NASDAQ:DRTX) advanced 5.50% to close the day at $16.89. Company monthly performance is recorded as 25.30%. Durata Therapeutics Inc (NASDAQ:DRTX) quarterly revenue growth is 18.53%.